Physician profile
Marla Strait
NPI 1063770659
$6,562.17
in general payments reported to CMS, 2019-2025
26 companies · $1,336 in 2025
The $1,336 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,298 · 2022: $1,660 · 2023: $1,356 · 2024: $912 · 2025: $1,336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,604.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,140.33 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $869.65 | 2021-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $631.99 | 2021-2025 | Verquvo, Capvaxive |
| Pfizer INC. | $606.70 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $538.70 | 2021-2025 | Brilinta, Lokelma, Andexxa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $425.47 | 2021-2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $399.64 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $301.33 | 2021-2024 | Jardiance |
| Boston Scientific Corporation | $267.46 | 2021-2024 | Watchman Access System |
| Abbvie INC. | $228.12 | 2023-2025 | |
| Kowa Pharmaceuticals America, INC. | $211.46 | 2021-2022 | |
| Novo Nordisk INC | $140.00 | 2021-2025 | Wegovy |
| Axsome Therapeutics, INC. | $121.88 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $109.74 | 2025 | Caplyta |
| Heartflow, INC. | $76.13 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $74.47 | 2021-2023 | Repatha |
| Lexicon Pharmaceuticals, INC. | $71.78 | 2023-2024 | Inpefa |
| Abbott Laboratories | $63.39 | 2021-2022 | |
| Daiichi Sankyo INC. | $58.34 | 2022-2023 | Injectafer |
| Evoke Pharma, INC. | $46.32 | 2023 | Gimoti |
| Cvrx, INC. | $43.97 | 2024-2025 | Barostim Neo System |
| Abiomed | $35.25 | 2024 | Impella |
| Amarin Pharma, INC. | $34.25 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $31.27 | 2025 | Camzyos, Eliquis |
| Lilly USA, LLC | $18.22 | 2025 | Zepbound, Mounjaro |
| Esperion Therapeutics, INC. | $16.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marla Strait listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.